Patient state of knowledge on biosimilars – do physicians need to improve education skills?

Availability of biosimilar medicines is rapidly increasing, potentially leading to a wider prescription and a support for healthcare system costs. Despite efforts of patient and physician educational initiatives there still remains a reluctance in prescribing or administering this type of products....

Full description

Bibliographic Details
Main Authors: Claudia Cobilinschi, Daniela Opris-Belinski, Catalin Codreanu, Razvan Ionescu, Magda Parvu, Claudia Mihailov, Horatiu Popoviciu, Codrina Ancuta, Elena Rezus, Ioana Saulescu, Sanziana Daia-Iliescu, Laura Groseanu, Ruxandra Ionescu
Format: Article
Language:English
Published: Amaltea Medical Publishing House 2020-06-01
Series:Romanian Journal of Rheumatology
Subjects:
Online Access:https://rjr.com.ro/articles/2020.2/RJR_2020_2_Art-05.pdf
Description
Summary:Availability of biosimilar medicines is rapidly increasing, potentially leading to a wider prescription and a support for healthcare system costs. Despite efforts of patient and physician educational initiatives there still remains a reluctance in prescribing or administering this type of products. A multi-centric survey was conducted on 336 patients with rheumatoid arthritis (RA), spondyloarthritis (SpA), psoriatic arthritis (PsA) or lupus (SLE) on biologic treatment. Half of the patients stated never hearing of biosimilars and one third feared adverse events (infections, cancer). Another 20% felt insecure on drug tolerability or efficacy. However, the majority declared relying on their rheumatologist if prescribing a biosimilar. Lack of patient information should be accurately addressed by health organizations so that the choice of treatment is done knowingly.
ISSN:1843-0791
2069-6086